Columnar cell lesions (CCLs) of the breast with low-grade/monomorphic-type cytologic atypia are being identified increasingly in biopsies performed owing to mammographic microcalcifications. The WHO Working Group on the Pathology and Genetics of Tumours of the Breast recently introduced the term 'flat epithelial atypia' (FEA) for these lesions. However, the ability of pathologists to reproducibly diagnose FEA and to distinguish it from CCLs without atypia has not been previously evaluated. Eight pathologists with an interest in breast pathology participated in a study to address this issue. The study reference pathologist provided the other seven study pathologists with a Powerpoint tutorial that included written criteria for, and representative images of, FEA and CCLs without atypia (ie, columnar cell change and columnar cell hyperplasia). Following review of the tutorial, the study pathologists examined images in Powerpoint format from 30 CCLs and were instructed to categorize each as either 'FEA' or 'not atypical'. Overall agreement among the eight pathologists was 91.8% (95% CI, 84.0-96.9%), and the multi-rater kappa value was 0.83 (95% CI, 0.67-0.94), which is within the 'excellent agreement' range. Agreement was slightly better for determining absence of FEA (92.8%: 95% CI, 84.1-97.4%), than for determining its presence (90.4%: 95% CI, 79.9-96.7%). We conclude that the diagnosis of FEA and its distinction from CCLs without atypia is highly reproducible with the use of available diagnostic criteria.
Columnar cell lesions (CCLs) of the breast represent a spectrum of histologic alterations that have in common the presence of columnar epithelial cells lining variably enlarged terminal duct lobular units. These lesions range in appearance from those characterized by a single layer of cytologically banal columnar cells to those in which the columnar cells exhibit sufficient cytologic and/or architectural atypia to raise the question of ductal carcinoma in situ (DCIS).
CCLs were first recognized about a century ago 1 and have subsequently been described by a number of authors under a wide variety of names. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Recently, there has been renewed interest in these lesions because they are being detected with increasing frequency in breast biopsies performed owing to mammographic microcalcifications. At this time, however, the lack of standardized terminology and the limited available information on their clinical significance has created difficulties with regard to both pathologic diagnosis of CCLs and the management of patients with these lesions. Recent observational studies as well as emerging genetic evidence suggest that some CCLs, particularly those with low-grade/monomorphic-type cytologic atypia, represent precursors to, or an early stage in the development of, low-grade DCIS. 7, 14, [16] [17] [18] [19] In fact, CCLs with cytologic atypia were initially recognized by Azzopardi as a form of DCIS that he designated 'clinging carcinoma'. 6, 7, 20 Subsequently, De Potter et al separated clinging carcinoma into two subtypes: clinging carcinoma with pleomorphic nuclei and clinging carcinoma with monomorphic nuclei. 21 The latter subgroup of lesions would fall under the recently proposed term 'flat epithelial atypia' (FEA). This term was introduced by the WHO Working Group on the Pathology and Genetics of Tumours of the Breast 16 to encompass CCLs with low-grade/monomorphic-type cytologic atypia that lacked the architectural features of atypical ductal hyperplasia or low-grade DCIS. Although the natural history of these lesions is poorly defined, prior studies have documented an association between FEA and the presence of synchronous atypical ductal hyperplasia (ADH), DCIS, invasive carcinoma (particularly, tubular carcinoma), and lobular neoplasia. 3, 5, 22, 23 Therefore, the identification of FEA and its distinction from non-atypical CCLs is a matter of practical importance to surgical pathologists and will be important for future studies of these lesions. At this time, however, the ability of pathologists to reproducibly separate FEA from CCLs without atypia is unknown. As a first step toward addressing this issue, we conducted a study to determine if eight pathologists with an interest in breast pathology could reproducibly distinguish FEA from non-atypical CCLs using available diagnostic criteria for these lesions.
Materials and methods
The study reference pathologist (SJS) prepared a tutorial in Powerpoint format that included written criteria for the diagnosis of columnar cell change and columnar cell hyperplasia (non-atypical CCLs) and for FEA, as well as representative digital images of each category of lesion. The diagnostic criteria for FEA used in this study were those adopted by the WHO Working Group on the Pathology and Genetics of Tumours of the Breast. 16 The criteria for the non-atypical CCLs used were those proposed by Schnitt and Vincent-Salomon. 13 These diagnostic criteria are summarized in Table 1 and illustrated in Figures 1-5 .
Following review of this training tutorial, the other seven study pathologists were provided with a test set of 30 CCLs (also prepared by the reference pathologist) that consisted of a Powerpoint file containing digital images of each case (three images for 21 of the cases, two images for seven of the cases, and four images for two of the cases). The participants were instructed to categorize each case as either 'FEA' or 'not atypical'. If a case was considered equivocal, the participants were instructed to place it in the 'not atypical' category.
The diagnoses of the reference pathologist and those of the other seven study pathologists were independently submitted directly to the study statistician (ME). The data were tallied and plotted, and unweighted multi-rater kappa statistics and percent agreement were calculated. 24 Percent specific agreement for the presence and absence of FEA was also calculated. 25 The 95% confidence intervals for kappa and percent agreement were obtained using the BCa bootstrap method, 26 based on 1000 bootstrap samples. These results are summarized in Figure 6 . Representative cases are illustrated in Figures 7-12 .
Discussion
The identification of CCLs is becoming increasingly common in breast biopsies performed owing to mammographic microcalcifications. A subset of these lesions is characterized by enlarged terminal duct lobular units in which the acini are lined by one to several layers of cuboidal to columnar epithelial cells with low-grade/monomorphic-type cytologic atypia similar to that seen in low-grade DCIS. Lesions with this constellation of features have long been recognized by pathologists under a Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast FP O'Malley et al wide variety of names including atypical cystic duct, 27 atypical lobules type A, 4 clinging carcinoma, 6, 20 hypersecretory hyperplasia with atypia, 8, 10 small ectatic ducts lined by atypical ductal cells with apical snouts, 5 columnar alteration with prominent apical snouts and secretions with atypia, 3 atypical cystic lobules, 9 ductal intraepithelial neoplasia-flat type, 18 and columnar cell hyperplasia (FEA) to describe these lesions. 16 While this term may be no better than any that have been suggested before it, it is now part of the WHO classification of Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast FP O'Malley et al tumors of the breast and, as such, we believe that it is prudent for pathologists to use it in clinical practice and in research studies at least in addition to, if not in place of, any of the other names that have been used to describe this lesion in the past.
Emerging evidence suggests that FEA may have an important role in neoplastic progression in the breast. 18, 19 Whereas its ultimate role in breast tumorigenesis remains to be more clearly defined, available observational data have indicated that FEA often coexists with other lesions for which the clinical implications and management considerations are better understood such as ADH, DCIS, invasive carcinoma (particularly tubular carcinoma) and lobular neoplasia. 3, 5, 22, 23 Therefore, the recognition of FEA is of importance for surgical pathologists because this serves as a 'red flag', particularly in core biopsies, for the possible presence of these other lesions.
A number of prior studies have addressed the issue of interobserver reproducibility in the diagnosis of proliferative breast lesions. [28] [29] [30] [31] [32] [33] One conclusion that can be drawn from these studies is that observer agreement is fostered by the use of standardized histologic criteria by the study participants. In keeping with this observation, the results of this study demonstrate for the first time that FEA, as defined by the WHO Working Group, can be distinguished from non-atypical CCLs with a high degree of consistency using available diagnostic criteria. In fact, the level of agreement we observed among eight pathologists in this study was higher than that seen in prior studies of observer agreement in proliferative breast lesions, even those in which standardized criteria were employed. 32 There are a number of potential limitations to this study. First, it could be argued that our results may not be representative of the level of agreement attainable in general pathology practice because all of the pathologists participating in this study have a particular interest in breast pathology. Second, the pathologists in this study were asked to render their diagnoses following examination of selected digital images rather than following examination of whole histologic sections under the microscope, as is done in routine clinical practice. However, given that the goal of this study was to assess observer variability in the classification of specific lesions, we believe that the use of digital images could be viewed as a strength of the study as this required the participants to base their diagnoses solely on the microscopic features of the lesions in question without the aid of surrounding histologic cues.
Criteria for the diagnosis of CCLs and FEA may continue to evolve as new knowledge about these lesions becomes available. However, the results of this study indicate that the diagnosis of FEA and its distinction from non-atypical CCLs (columnar cell change and columnar cell hyperplasia) is highly reproducible with the use of currently available diagnostic criteria. The use of these criteria in clinical practice and in future research studies evaluating the molecular biology and clinical significance of these lesions should help improve patient care and communication between pathologists and with clinicians, and should help advance our understanding of these lesions.
